Stronger STD Warning For Vaginal Antifungals Suggested By Advisory Cmte.
This article was originally published in The Tan Sheet
Executive Summary
Prominent, more specific cautionary statements in OTC vaginal anitfungal labeling to help ensure consumers do not misdiagnose more serious conditions, such as sexually transmitted diseases, for a yeast infection, were supported by FDA advisory committee members at a Sept. 11 meeting in Bethesda, Md.
You may also be interested in...
Yeast Infection OTC Misuse Unimproved With Prior Physician Diagnosis
A past physician diagnosis of a yeast infection does not improve a woman's ability to self-diagnose the condition, researchers report in the March issue of Obstetrics & Gynecology
Yeast Infection OTC Misuse Unimproved With Prior Physician Diagnosis
A past physician diagnosis of a yeast infection does not improve a woman's ability to self-diagnose the condition, researchers report in the March issue of Obstetrics & Gynecology
Yeast Infection OTC Misuse Unimproved With Prior Physician Diagnosis
A past physician diagnosis of a yeast infection does not improve a woman's ability to self-diagnose the condition, researchers report in the March issue of Obstetrics & Gynecology
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: